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ABSTRACT
Transglutaminase type 2 (TG2) is an extracellular matrix crosslinking enzyme with a pivotal role in kidney
ﬁbrosis. The interaction of TG2with the heparan sulfate proteoglycan syndecan-4 (Sdc4) regulates the cell
surface trafﬁcking, localization, and activity of TG2 in vitro but remains unstudied in vivo. We tested the
hypothesis that Sdc4 is required for cell surface targeting of TG2 and the development of kidney ﬁbrosis in
CKD. Wild-type and Sdc4-null mice were subjected to unilateral ureteric obstruction and aristolochic acid
nephropathy (AAN) as experimental models of kidney ﬁbrosis. Analysis of renal scarring by Masson tri-
chrome staining, kidney hydroxyproline levels, and collagen immunoﬂuorescence demonstrated progres-
sive ﬁbrosis associated with increases in extracellular TG2 and TG activity in the tubulointerstitium in both
models. Knockout of Sdc-4 reduced these effects and prevented AAN-induced increases in total and
active TGF-b1. In wild-type mice subjected to AAN, extracellular TG2 colocalized with Sdc4 in the tubular
interstitium and basement membrane, where TG2 also colocalized with heparan sulfate chains. Hepariti-
nase I, which selectively cleaves heparan sulfate, completely abolished extracellular TG2 in normal and
diseased kidney sections. In conclusion, the lack of Sdc4 heparan sulfate chains in the kidneys of Sdc4-null
mice abrogates injury-induced externalization of TG2, thereby preventing proﬁbrotic crosslinking of ex-
tracellular matrix and recruitment of large latent TGF-b1. This ﬁnding suggests that targeting the TG2-
Sdc4 interaction may provide a speciﬁc interventional strategy for the treatment of CKD.
J Am Soc Nephrol 25: ccc–ccc, 2014. doi: 10.1681/ASN.2013050563
CKD is characterized by glomerulosclerosis and
tubulointerstitial ﬁbrosis that result from excessive
extracellular matrix (ECM) accumulation.1–3 In re-
cent years, the role of transglutaminase type 2
(TG2) has been shown to be crucial to both the
ECM expansion1,4,5 and TGF-b1 activation6–9
that underlies this ﬁbrotic remodeling.
TG2 belongs to the eight-member transgluta-
minase family that catalyzes a calcium-dependent
acyl-transfer reaction (EC 2.3.2.13) between the
g-carboxamide group of peptide-bound glutamine
and the «-amino group of peptide-bound lysine,10
generating stable «-(g-glutamyl)-lysine isopeptide
crosslinks. In ﬁbrotic diseases (e.g., renal, liver, and
pulmonary ﬁbrosis), increased TG2 externalization
and/or expression results in abundant crosslink
formation, contributing to ECM accumula-
tion.5,7,11–16 In early CKD, «-(g-glutamyl)-lysine
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Figure 1. Protective effect of Sdc44-KO on the development of renal ﬁbrosis in the UUO model of CKD. ParafﬁnQ:11 sections from WT and
Sdc4 KO kidneys (control and 21 days after UUO) were stained with MT (A–D), collagen I (E–H), collagen III (I–J), and collagen IV (M–P).
Collagen staining (red) and nuclei staining (blue). Representative images at 3200 magniﬁcation are shown. Detail of collagen IV
staining at 3400 magniﬁcation is shown (M).
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crosslinking in the ECM results predominantly from cell ex-
ternalization of existing TG2 as the renal TG2 level remains
constant.4 The externalized TG2 is known to exert a
proﬁbrotic function also through a nonenzymatic “structural”
activity, by enhancing arginine-glycine-aspartic acid–inde-
pendent cell adhesion and, consequently, contraction of the
Figure 2. Protective effect of Sdc4-KO of the development of renal ﬁbrosis in the AAN model of CKD. Parafﬁn sections from WT and
Sdc4 KO kidneys (control and AAN at 12 weeks) were stained with MT (A–D), collagen I (E–H), collagen III (I–L), and collagen IV (M–P).
Collagens staining (green) and nuclei staining (blue). Representative images at 3200 magniﬁcation are shown.
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ECM.17–19 In experimental CKD, pan TG inhibition preserved
kidney function because of a reduction in kidney ﬁbrosis in
both diabetic and nondiabetic disease.2,16 Mice deﬁcient in
TG2 were protected against the development of ﬁbrosis in
obstructive nephropathy resulting from impaired collagen I
synthesis related to decreased TGF-b1 activation.8
However, clinical application of anti-TG2 therapy has been
prevented by the inability to develop TG2-speciﬁc inhibitors
due to a highly conserved catalytic core across the TG family,10
with inhibition of factor XIIIa and the keratinocyte transglu-
taminase causing particular concern.20 Consequently, eluci-
dation of the mechanism whereby TG2 is released from cells
has been an object of intense scrutiny, because TG2 is uncon-
ventionally secreted via a potentially unique non-Golgi
route,21,22 which may offer a speciﬁc interventional strategy
to decrease extracellular TG2.
Recently, we have shown that heparan sulfate proteoglycans
(HSPG), such as syndecan-4 (Sdc4), may have a key role in the
cell surface trafﬁcking of TG2 in vitro.23 Sdc4 and TG2 coas-
sociated in cell membranes via the HS chains of Sdc4, for
which TG2 has high afﬁnity.18,23,24 Lack of Sdc4/HS or func-
tional inhibition of HS led to a lower level of cell-surface TG2
antigen and crosslinking activity in vitro and a parallel
accumulation of cytosolic TG2 with no changes in the total
level of TG2 expression.23 Membrane-proximal Sdc4/HS may,
therefore, affect the unconventional secretion of TG2, as de-
scribed for ﬁbroblast growth factor-2, by acting as a cell-sur-
face “molecular trap.”25 Therefore, Sdc4/HS may modulate
TG2 proﬁbrotic function by controlling its cell-surface traf-
ﬁcking. Sdc4/HS has also been implicated in kidney ﬁbrosis,
being upregulated in progressive proliferative kidney diseases
(IgA nephropathy) and diabetic nephropathy, but not in non-
proliferative diseases.26–28
To investigate the possible role of Sdc4 in regulating cell-
surface trafﬁcking of TG2 in vivo, we induced kidney ﬁbrosis in
Sdc4-knockout (KO) mice29 and assessed whether or not Sdc4
deletion affected TG2 externalization/extracellular activity
and tubulointerstitial ﬁbrosis development. We used two dis-
tinct experimental models of kidney ﬁbrosis: unilateral ure-
teric obstruction (UUO)30 and aristolochic acid nephropathy
(AAN).31,32 Sdc4-KO ameliorated tubulointerstitial ﬁbrosis in
both models, and deletion of Sdc4 led to a lowering of extra-
cellular TG2 in the ECM. Binding of TG2 to the tubular in-
terstitium depended on the HS chains of proteoglycans, with
which TG2 was found to be strongly associated in normal and
diseased kidney. These data suggest for the ﬁrst time that Sdc4
Figure 3. Quantiﬁcation of the protective effect of Sdc4 in the UUO and AAN models of CKD. Graphical presentation of kidney ﬁbrosis
in the UUO (A–D) and AAN (E–H) ﬁbrotic lesions. The ﬁbrosis score was calculated by multiphase analysis of MT-stained kidney sections
as the ratio blue/green (collagen)/pink/red (tissue area) (A and E). Deposition of collagen I (B and F), collagen III (C and G), and collagen
IV (D and H) was measured by multiphase analysis of immunoﬂuorescence-stained kidney sections (collagens/DAPI). All data were
normalized by the WT control at the lower time point (day 7 for UUO, week 9 for AAN). Raw data at these time points were the fol-
lowing: MT UUO, 0.02; MT AAN, 0.001; collagen I UUO, 0.01; collagen I AAN, 0.03; collagen III UUO, 0.04; collagen III AAN, 0.06;
collagen IV UUO, 0.03; collagen IV AAN, 0.08. *P,0.05 versus control; †P,0.05 versus Sdc4-KO UUO or AAN; aP,0.05 versus WT day
7 UUO or week 9 AAN; bP,0.05 versus Sdc4-KO day 7 UUO or week 9 AAN; cP,0.05 versus WT day 14 UUO; dP,0.05 versus Sdc-KO
day 14 UUO.
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plays a critical role in the pathogenesis of kidney ﬁbrosis by
regulating TG2 trafﬁcking and localization viaHS chain-bind-
ing.
RESULTS
Kidney Fibrosis Is Reduced in Sdc4-Null Mice
The phenotype of Sdc4-KO mice was investigated in two
models of CKD: UUO and AAN. Both models led to the
progressive development of interstitial ﬁbrosis in wild-type
(WT) kidneys as assessed by Masson trichrome (MT) staining
(Figures 1, A and B, and 2, A and B). Fibrotic areas caused by
Aristolochic acid I (AAI) were mainly located in the outer
cortex with areas of scarred tissue tracking down the medul-
lary ray, whereas in the UUO, there was a more diffuse ﬁbrosis
through the cortex. Sdc4 deletion resulted into a reduced col-
lagen staining in both models compared
with WT (Figures 1D and 2D). There
were no differences between WT and
Sdc4-KO kidneys at baseline (Figures 1, A
and C, and 2, A and C).
Multiphase image analysis of collagen-
positive staining on MT sections revealed
that in the UUO model the increase in
collagen was signiﬁcant compared with the
change in controls at all the time points
(P,0.05) (Figure 3A), while differences
between WTand Sdc4-KO ﬁbrotic kidneys
were signiﬁcant at days 7 and 21 after UUO
(Figure 3A). In the AAN model, MT stain-
ing was signiﬁcantly higher than the con-
trol at 12 weeks (Figure 3F), with a reduc-
tion of MT staining in the Sdc4-KO
compared with WT ﬁbrotic kidneys (Fig-
ure 3F). In both models, ﬁbrosis develop-
ment was slower in Sdc4-KO mice than in
the WT (Figure 3, A and F). Whole-kidney
hydroxyproline analysis conﬁrmed the
progressive increase of collagen in both
models of ﬁbrosis, with lower collagen ac-
cumulation in Sdc4-KO at day 21 after
UUO and at 12 weeks in the AAN model
(Figure 3, B and G).
Individual changes in the levels of col-
lagen I, III, and IV were analyzed by
immunoﬂuorescence on parafﬁn sections
fromWTand Sdc4-KOkidneys. There were
no signiﬁcant differences in any collagen
staining in control kidneysbetweenWTand
Sdc4-KO mice (Figures 1 and 2, E, G, I, K,
M, O). All collagens were increased in dis-
eased kidneys, particularly so in WT kid-
neys (Figures 1 and 2, F, J, N) compared
with Sdc4-KO kidneys (Figures 1 and 2,
H, L, P). These differences were conﬁrmed by multiphase im-
age analysis of the staining for collagen I (Figure 3, C and H),
collagen III (Figure 3, D and I), and collagen IV (Figure 3, E
and J) from both CKD models. In diseased animal, kidneys
from Sdc4-KO mice showed reduced levels of collagen I de-
position compared with WT at days 7 and 21 in the UUO
model (Figure 3C) and at 12 weeks in the AAN model (Figure
3H). Lower levels of collagen III accumulation were also de-
tected at day 21 in Sdc4-KO obstructed kidneys (UUO) com-
pared with WT (Figure 3D), but not in response to AAI (Fig-
ure 3I). Changes in collagen IV, typically abundant in the
tubular and glomerular basement membranes, were greater
in the WT than in the Sdc4-KO obstructed kidneys at 21 days
after UUO (Figure 3E) and at 12 weeks in the AAN model
(Figure 3J). Evaluation of collagen gene expression by quali-
tative RT-PCR analysis revealed signiﬁcant elevation of inter-
stitial collagen a1(I) and collagen III transcripts and the
Figure 4. Sdc4-KO decreases extracellular TG2 and TG activity in the UUO model of
CKD. Extracellular TG2 and TG in situ activity (ISA) were detected on cryostat sections
of WT and Sdc4 KO kidneys from the UUO model through immunoﬂuorescence (A
and B). Representative images from control and UUO kidneys (3200 magniﬁcation)
are shown. The levels of TG2 (C) and TG ISA (D) were quantiﬁed by multiphase
analysis; TG2 was quantiﬁed by dividing TG2 signal for DAPI, while TG ISA by dividing
incorporated Texas red cadaverine by tissue area (green autoﬂuorescence). All data
were normalized by the WT control at day 7 UUO; the original values were 0.098 for
TG2 and 3.564 for TG ISA. *P,0.05 versus control; †P,0.05 versus Sdc4 KO UUO.
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basement membrane collagen IV transcript in the UUO mice
and AAI-treatedmice compared with the controls. There was a
lower expression level in the Sdc4-KO mice, which was signif-
icant for collagen a1(I), III, and IV in the AAN model but
reached signiﬁcance only for collagena1(I) in the UUOmodel
(Supplemental Figure 1). Therefore, the knockout of Sdc4
caused a reduction in the development of kidney ﬁbrosis in
both models, and this was principally due to less deposited
collagen.
The kidney weight to body weight ratio was lower in AAN
but was preserved in the Sdc4-KO mice (Supplemental Figure
2A). Serum creatinine and creatinine clearance were respec-
tively increased and decreased (P,0.05) in response to AAI
but with no difference between the two genotypes. However,
in this model, loss in functionwas higher at 9 weeks when only
an early level of ﬁbrosis was seen (Figure 3F), than after 12
weeks when ﬁbrosis was more advanced (Supplemental Figure
2, B and C).
Sdc4-KO Lowers Extracellular TG2 in
Two Mouse Models of CKD
The link between TG2 externalization and
tubulointerstitial ﬁbrosis is well known,1
being associated with post-translational
modiﬁcation of the ECM and the recruit-
ment of large latent TGF-b1 that facilitates
its activation.6,8,9,33,34 Therefore, we exam-
ined the consequences of Sdc4-KO on ex-
tracellular TG2 in normal and diseased kid-
neys. Extracellular TG2 antigen was
speciﬁcally detected on unﬁxed cryosec-
tions after washout of the intracellular en-
zyme.1,12 Extracellular TG2 was mainly lo-
calized in the tubulointerstitial space and
within the glomerular tuft (most likely
within the mesangial matrix and glomeru-
lar basement membrane) in normal kid-
neys from WT and Sdc4-KO mice, with
no quantitative difference in the level of
extracellular TG2 between WT and Sdc4-
KO control mice (Figures 4 and 5). In the
UUO model, the levels of TG2 increased
with the progression of kidney ﬁbrosis in
the tubulointerstitium, with the WT kid-
neys having signiﬁcantlymore extracellular
TG2 than the Sdc4-KO kidneys at 14 and 21
days after UUO (Figure 4, A and C, Sup-
plemental Figure 3).
In a manner similar to that seen in the
UUO, there was progressive accumulation
of extracellular TG2 in response to AAI
(Figure 5A). Again, the level of externalized
TG2 was signiﬁcantly higher in the WTan-
imals than in the Sdc4-null mice in the
AAI-treated mice at 12 weeks (Figure 5, A
andC). Extracellular TG activity (Figures 4B and 5B)mirrored
the distribution of TG2 antigen, with no quantitative differ-
ence in level betweenWTand Sdc4-KO control kidneys. UUO
and AAN kidneys had a signiﬁcantly higher level of TG activity
at all the time points compared with the relative controls (Fig-
ures 4D and 5D). In the UUO, althoughmean extracellular TG
activity was always higher in WT than in Sdc4-KO kidneys,
this difference reached signiﬁcance from day 14 (Figure 4D).
In the AAN, extracellular TG activity was higher inWT than in
Sdc4-KO kidneys at 12 weeks (Figure 5D). Western blot anal-
ysis of total homogenates revealed no differences in TG2 ex-
pression between the two genotypes (WT and Sdc4-KO) in
control and diseased kidneys (Figure 6). This rules out the
possibility that the lower extracellular TG2 detected in the
Sdc4-KO kidneys that underwent experimental ﬁbrosis was
due to any difference in TG2 production between the two
genotypes. Therefore, TG2 was elevated outside the cell in
both models (Figures 4 and 5) through an increase in cellular
Figure 5. Sdc4-KO decreases extracellular TG2 and TG activity in the AAN model of
CKD. Extracellular TG2 was detected using cryostat section of WT and Sdc4-KO
kidneys from the AAN model through immunoﬂuorescence (A). TG in situ activity was
measured by incorporation of biointylated cadaverine revealed by TexasRed-labeled
streptavidin (B). Quantiﬁcation of levels of TG2 (C) and TG in situ activity (D) were
performed using multiphase image analysis by dividing incorporated TG2 or TG ac-
tivity by tissue area (green autoﬂuorescence). All data were normalized by the WT
control at week 9; the original values were 0.04 for TG2 and 0.03 for TG in situ activity.
*P,0.05 compared to control; †P,0.05 compared to Sdc4-KO AAN; achanges from 9
and 12 weeks in the WT AAN groups.
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trafﬁcking, rather than an upregulation per se, which was de-
ﬁcient in Sdc4-KO diseased kidneys.
Because TG2was not found in the ECMof Sdc4-KO ﬁbrotic
kidney sections to the same extent as in the ECM of WT
diseased kidneys, we analyzed whether it was retained in-
tracellularlyor in the cytosol.WTandSdc4-KOﬁbrotic kidneys
were fractionated into cytosol and membrane fractions, and
equal loading of protein fractions was analyzed by Western
blotting for TG2 expression. Sdc4-KO membrane fractions
contained signiﬁcantly less TG2 antigen than did the WT
membrane fractions (Figure 7, A andD). Conversely, the Sdc4-
KO cytosolic fractions had a higher amount of TG2 antigen
compared with the WT (Figure 7, B and D). The combined
level of TG2 was not signiﬁcantly different in the two geno-
types (Figure 7, C andD).We next visualized intracellular TG2
in parafﬁn sections, where ECM TG2 cannot be detected.1,12
Compared with the WT ﬁbrotic kidneys, staining of Sdc4-KO
sections revealed an increase in cytosolic TG2 that was paral-
leled by a lower level of externalized TG2 after UUO, as spe-
ciﬁcally detected in cryostat sections (Figure 7E).12 This ﬁnd-
ing is consistent with our prior data that Sdc4-null cells had an
increased retention of TG2 inside the cell.22 Therefore, Sdc4
inﬂuences the externalization of proﬁbrotic TG2.
Extracellular TG2 Availability in the Renal Interstitium
Depends on Binding to HSPG
To investigate the mechanism of Sdc4 modulation of TG2
externalization, we began with visualizing extracellular TG2
and Sdc4 in normal and ﬁbrotic kidneys after AAI. Immuno-
ﬂuorescence analysis of unﬁxed cryostat sections revealed, in
normal tissues, that Sdc4 and TG2 had mainly a tubular
basement membrane localization; however, Scd4 staining was
morediffuse and clearlyoutlined theperimeter of all cells of the
renal interstitium, in keeping with its matrix cell-receptor role
(Figure 8). In AAN kidneys, extracellular TG2 staining was
more intense and ﬁlled the widened interstitial space, deco-
rating the thickened basement membrane. Extracellular TG2
and Sdc4 clearly showed a parallel alignment with areas of
intense extracellular TG2 staining lying adjacent to Sdc4 stain-
ing in AAN kidneys (Figure 8). Quantitative colocalization
analysis according to Manders35 indicated a good overlap co-
efﬁcient (mean6SEM, 0.6760.07 [1 is total colocalization]).
The Pearson correlation coefﬁcient was 0.6460.04. The par-
tial overlap and location in immediately adjacent regions, es-
pecially in the basement membrane, suggested that TG2 asso-
ciation with Sdc-4 could be mediated by the sulfated domains
within HS chains, rather than the HSPG core protein. Synde-
cans are characterized by three to ﬁve GAG chains,36 which
typically vary in length and size, extending extensively in the
extracellular space. Dual staining of extracellular TG2 and HS
in sections from control and AAN kidneys (Figure 9) showed
that HS were strongly expressed in the tubulointerstitium and
were prominent in the basement membranes of the diseased
kidney, where HS largely colocalized with TG2. Quantitative
colocalization indicated an improved overlap coefﬁcient
Figure 6. The expression of TG2 in kidney is similar in the WT and
Sdc4-KO genotype. TG2 expression was evaluated by Western
blot in control kidneys and ﬁbrotic kidneys (total homogenates)
from WT and Sdc4 KO mice. (A) AAN model. (B) UUO model.
Cyclophilin A (Cyp A) was used as loading control. Twenty-ﬁve
micrograms of kidney proteins was used, and 100 ng guinea pig
liver TG2 was loaded as a control (M). TG2 protein level is ex-
pressed as mean6SEM of TG2/Cyp A (TG2 level); data are nor-
malized for WT control. Differences in TG2 between the two
genotypes and treatments were nonsigniﬁcant (P.0.05).
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(0.8560.09) and Pearson correlation coefﬁcient (0.7760.08).
To conﬁrm that TG2-association with the interstitial matrix
depended on binding to the HS chains of proteoglycans, sec-
tions were preincubated with heparitinase I to selectively
cleave HS (Figure 10). Following hepariti-
nase I pretreatment, both the interstitial
space and the basement membrane were
almost completely devoid of TG2 binding,
indicating that HS plays a critical role in the
cell-surface availability of TG2 (Figure 10).
Because we showed that Sdc-4 is critical
to the availability of cell-surface TG2 in the
diseased kidney (Figures 4 and 5), these
ﬁndings suggest a role for the Sdc4-HS
chains in recruiting TG2 at the basolateral
membrane and the renal interstitium in
progressive kidney ﬁbrosis. HS not only
characterized membrane HSPG but also
secreted proteoglycans.37 It would be rea-
sonable to think that once TG2 is external-
ized in the renal interstitium, through the
critical involvement of transmembrane
Sdc4, it may be trafﬁcked in the matrix by
binding to basement membrane HSPG.
Sdc4-KO Reduces TGF-b1 Activation
Given that TG2 is involved in the activation
of TGF-b1 by recruiting large latent TGF-b
complex,6,9,33,34 and failure to localize/re-
cruit latent TGF-b1 results in altered TGF-
b1 activity, the level of active TGF-b1 was
evaluated through the mink lung bioassay
(Figure 11).34,38 Active TGF-b1 was similar
in WT and Sdc-4 KO control kidneys. Ac-
tive TGF-b1 was increased in the ﬁbrotic
kidneys of WT mice at 12 weeks of AAI
treatment compared with controls but
was not elevated to the same extent in the
Sdc4-KO AAI-treated kidneys (Figure
11A). Total TGF-b1 was also signiﬁcantly
elevated in the ﬁbroticWT kidneys and not
in the Sdc4-KO kidneys (Figure 11B).
Overall, the percentage of active TGF-b1
in the WT AAI-treated kidneys was signif-
icantly higher than in the Sdc4-KO AAI-
treated kidneys (Figure 11C). Syndecan-2
(Sdc2), the main syndecan protein found
to directly interact with TGF-b1,39 was not
differently expressed in the Sdc4-KO nor-
mal and diseased kidneys compared with
WT counterparts (Supplemental Figure
2). Therefore, we have conﬁrmed a reduc-
tion in TGF-b1 activity associated with
Sdc4 deletion.
Figure 7. Sdc4-KO reduces the cell membrane targeting of TG2. TG2 expression was
quantiﬁed by Western blot in the AAN kidneys from WT and Sdc4 KO mice (A–D).
Kidney homogenates were fractionated as described in the Supplemental Methods.
Forty-micrograms of kidney proteins was loaded. Cyclophilin A (Cyp A) was used as
loading control, and b-tubulin and Na+/K+ ATPase were used as cytosolic and
membrane markers, respectively. TG2 protein level is expressed as mean6SEM of
TG2/Cyp A (TG2 level); data are normalized for WT membrane fraction. *P,0.05. (D).
Extracellular TG2 was detected in cryosections and intracellular TG2 was im-
munostained in parafﬁn sections through immunoﬂuorescence. Details of represen-
tative images of extracellular TG2 staining (Supplemental Figure 3) and representative
images of intracellular TG2 overlapped to phase contrast at day 21 after UUO are
shown at 3400 and 3630 magniﬁcation, respectively (E). Scale, 50 mm.
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DISCUSSION
All types of CKD progress to kidney failure through the
common pathway of kidney ﬁbrosis and scarring. Therefore,
understanding the mechanisms involved in this is essential for
the development of antiﬁbrotic therapies. Studies have re-
peatedly highlighted the beneﬁt of TG2 modulation on the
progression of kidney ﬁbrosis, but the tightly conserved
catalytic triad within the TG family prevents the design of
speciﬁc small-molecule TG2 inhibitors. In this paper, we have
exploited recent in vitro observations that Sdc4 may have an
important role in TG2 export and retention of TG2 at the cell
surface,23,40,41 toQ:3 see whether or not targeting the TG2-Sdc4
interaction may provide such an interventional step.
We have chosen to do these studies in twomodels of CKD in
parallel in order to prevent concerns over any model-speciﬁc
responses. UUO is a well established model for rodents that
allows the ﬁbrotic state to be developed in a
relatively short time without the use of
exogenous toxins and the development of
uremia.42 Although obstruction of the uri-
nary tract has clinical relevance,43 the in-
terstitial ﬁbrosis of this model is not typical
of most types of CKD. Therefore, we have
also used the relatively new AAN model,
which does provide a typical tubulointer-
stitial ﬁbrosis.31,32,44
The results in both models were highly
consistent with lower levels of ﬁbrosis
detected in the Sdc4-KO animals,
suggesting a protective role for Sdc4-KO
in kidney ﬁbrosis. Because ﬁbrosis is an
abnormal tissue repair process, this result
ﬁts with the involvement of Sdc4 in wound
healing and the reported delay in wound
repair in Sdc4-KO mice.45,46
Although, to our knowledge, this is the
ﬁrst study in CKD using Sdc4-KO mice,
Sdc4-KO was investigated in mice with
unilateral nephrectomy.47 Glomeruloscle-
rosis was reported in Sdc4-KO male mice
after and was attributed to the compensa-
tory expression of Sdc2 and activation of
TGF-b1.47 However, unilateral nephrec-
tomy typically causes renal hypertrophy
rather than overt ﬁbrosis and, subse-
quently, is not similar to the two CKD
models used here. Moreover, we did not
see Sdc2 compensation in Sdc4-KO mice
after UUO.
Extracellular TG activity positively cor-
relatedwithﬁbrosis development in the two
experimental models of renal ﬁbrosis. To
establish whether or not the protective
effect of Sdc4-KO was related to its previously reported role
in TG2 trafﬁcking/cell-surface localization,23,41 tissues were
subjected to assays for both extracellular TG2 antigen and in
situ TG activity. In both models, increased extracellular TG2
and TG activity was found to be in the same interstitial and
periglomerular regions where increased collagen deposition
was detected. Importantly, the increase in extracellular TG2
occurred in parallel with ﬁbrosis, being signiﬁcantly lower in
the Sdc4-KO diseased animals. Because the total TG2 level was
similar in both WTand Sdc4-null mice, the difference in TG2
antigen outside the cell could only be due to Sdc4 affecting the
cell-surface availability of TG2. This conclusion was corrobo-
rated by the ﬁnding of reduced distribution of TG2 to the
membrane and a higher proportion of cytosolic TG2 follow-
ing Sdc4 silencing in kidney, consistent with similar ﬁndings
in dermal ﬁbroblasts from Sdc-4 KO mice.23 Taken together,
the in vivo and ex vivo data strongly support the hypothesis
that Sdc4 plays a signiﬁcant role in TG2 export and
Figure 8. TG2 partially colocalize with Sdc4 core protein in tubulointerstitial ﬁbrotic
lesions. Sdc4 and TG2 immunostaining of cryostat sections was performed by using
rabbit polyclonal anti-Sdc4 and mouse monoclonal anti-TG2 IA12 antibody followed
by, respectively, donkey antirabbit AlexaFluor 488 and goat antimouse DyLight 594.
Representative confocal images of Sdc4, TG2, and DAPI stained sections are shown
separately and merged (with and without DAPI staining) for control and AAI-treated
kidneys (two ﬁbrotic lesions are shown, ﬁeld 1 and ﬁeld 2). Basolateral membrane
localization of Sdc4 and TG2 after AAI is shown at higher magniﬁcation (details a, b, and
c). Dual staining controls were carried out in kidney sections from TG2 KO and Sdc4 KO
mice (Supplemental Figure 3). Scale bars are shown under each column of images.
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localization and that interference with TG2-Sdc4 interaction
may have therapeutic value.
In the tubular epithelial cell line NRK-52E, we previously
reported that TG2 is transported basolaterally into the tubular
basement membrane through an unconventional pathway,
most likely linked to direct molecular trap involving trans-
membrane transport.21 Here we have shown for the ﬁrst time
that HS are critical for extracellular TG2 association with the
tubular basement membrane. Therefore, TG2 is likely to be
“trapped” by HS as soon as secreted from the plasma mem-
brane (diagram a in Figure 12). The components required for
TG2-membrane translocation are unknown, but the mem-
brane-proximal HS chains of Sdc4 are a key factor. TG2 is a
high-afﬁnity ligand for heparin/HS with a dissociation con-
stant in the low nanomolar range,22 and folding of TG2
forms a functional heparin-binding domain.24 Upon injury-
induced tissue damage, the externalized TG2 is thought to be
activated by the increased calcium ions and
low guanine nucleotides,10 leading to ma-
trix stabilization by crosslinking of ﬁbro-
nectin and collagen. Although not tested,
it is conceivable to speculate that further
diffusion of TG2 from the cell surface
may be regulated by shedding of TG2-
Sdc4 from the cell surface by matrix metal-
loproteases, which are abundant, into a
wound healing/ﬁbrotic context. Further-
more, the HS chains could facilitate diffu-
sion of TG2 through dissociation/reassoci-
ation via adjacent binding sites, thus
allowing TG2 to “slide” in the matrix, de-
pending on the speciﬁcity of the HS inter-
action. The signiﬁcant but partial attenua-
tion of extracellular TG2 activity and
export in two Sdc4-KO mice models of
CKD, and its complete abolishment by di-
gestion of the HS chains, suggest that addi-
tional HSPG may be implicated in TG2 lo-
calization in the renal interstitium.
Secreted proteoglycans, such as perlecan,
agrin, and collagen VIII (typical glomeru-
lar basement membrane proteoglycans),
are also expressed in the tubule intersti-
tium.37 Taken together, our ﬁnding sug-
gests that TG2 cell-surface availability
may depend on trapping of TG2 by the
HS chains of transmembrane HSPG Sdc4.
Further engagement of TG2 with basement
membrane–secreted HSPG may facilitate
the distribution of extracellular TG2 into
the matrix.
Our ﬁndings support the idea that Sdc4
and TG2 cooperate in the ﬁbrotic process
and Sdc4-KO reduces ﬁbrosis through this
route. In addition to controlling thecell-surfaceavailability and
function of extracellular TG2, Sdc4 regulates the export of
other ﬁbrogenic factors, such as ﬁbroblast growth factor-2.25
Sdc4/HS have also been shown to inﬂuence and integrate the
procontractile signals from TGF-b1, leading to increased cell
adhesion during scarring,48 and trapping of exogenously pro-
vided TGF-b.49 TG2 participates in the TGF-b1 recruitment/
activation cascade by crosslinking the amino-terminal region
of LTBP-1 to ECM proteins (diagram c in Figure 12).6,33,50
This, together with matrix accumulation and stabilization by
direct post-translational modiﬁcation of ECM proteins (dia-
gram b in Figure 12), is accountable for the ﬁbrotic role of TG2
in vivo.8,34 Of note, we found the protective role of Sdc4-KO
on ﬁbrosis to be associated with lower activation of TGF-b1.
This is predictable given the lower TG2 activity in the ECM.
The TG2-KO mouse is protected against kidney UUO-in-
duced ﬁbrosis8 and pulmonary ﬁbrosis,7 and this is due partly
to lower levels of proﬁbrotic active TGF-b1 in the damaged
Figure 9. TG2 largely colocalize with HS chains in tubulointerstitial ﬁbrotic lesions. HS
and TG2 immunostaining of cryostat sections was performed using mouse monoclonal
anti-HS antibody and rabbit polyclonal anti-TG2 antibody, followed by, respectively,
goat anti-mouse (IgM) FITC and donkey anti-rabbit IgG AlexaFluor 568. Representative
pictures of HS, TG2, and DAPI-stained sections are shown separately and merged (with
and without DAPI staining) for control and AAI-treated kidneys (two ﬁbrotic lesions are
shown). Basolateral membrane and interstitial localization of HS and TG2 after AAI are
shown at higher magniﬁcation (details a, b, and c). Dual staining controls were carried
out in TG2 KO kidney sections (Supplemental Figure 3). Scale bars are shown under
each column of images.
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organ or bronchoalveolar lavage, respectively.7 Given that
Sdc4-KO leads to lower extracellular TG2, which is needed
for one of the three known mechanisms of TGF-b1 recruit-
ment and activation51 then it is reasonable to suggest that the
lower active TGF-b1 is affected by impaired TG2 recruitment
of the LTBP. Although a direct role of Sdc4 in TGF-b1 activa-
tion has not been reported, the ability of Sdc4 to act as a res-
ervoir of growth factors leaves open the possibility of a syner-
gistic action between TG2 and Sdc4 in TGF-b1 activation
(diagram d in Figure 12). Therefore, because Sdc4 and TG2
affect multiple pathways in the ﬁbrotic program, targeting the
TG2-Sdc4 interaction, would probably form part of a multi-
faceted interventional strategy against ﬁbrosis.
A surprising ﬁnding in this study is that
although Sdc4-KO is clearly protective,
with strong reduction in ﬁbrosis in both
models of kidneyﬁbrosis, this didnot have a
knock-on effect on kidney function in the
AANmodel. Themost obvious explanation
is that the AAN is primarily a model of
tubulointerstitial ﬁbrosis. At 12 weeks,
there was only minimal glomerulosclerosis
because the disease had not gained glomer-
ular involvement at this stage. It is therefore
not surprising that there was no effect on
glomerular ﬁltration. This raises the ques-
tion as to why both WT and Sdc4-KO
animals treated with AAI had elevated
serum creatinine and lower clearance at
both time points. In rodents and mice
especially, creatinine is secreted from the
tubules and because AAI is cytotoxic to the
tubular epithelial cells; this would clearly
interfere with creatinine excretion through
this route. Thus, because serum creatinine
decreased from 9 to 12 weeks, this simply
reﬂected the epithelial cell recovery to AAI
toxicity, which undoubtedly masked any
early ﬁbrotic changes on kidney function
due to ﬁbrosis.
In conclusion, Sdc4-KO is protective in
two models of tubulointerstitial ﬁbrosis. In
both cases this is related to a reduction of
extracellular TG2 antigen and activity,
which has previously been shown to be a
primary cause of scar tissue formation in
renal ﬁbrosis by both direct post-transla-
tional modiﬁcation and indirect TGF-b1
recruitment. Therefore, Sdc4 is involved
in extracellular trafﬁcking and cell-surface
targeting of proﬁbrogenic TG2 in vivo.
These data may ultimately be useful in de-
signing interventional strategies for CKD.
CONCISE METHODS
Experimental Models
Experimental UUO was performed on Sdc4-KO29 and control
C57BL/6J mice. Anesthesia was induced with 5% ﬂuorothane and
maintained by 2% ﬂuorothane during the surgical process, wherein
the left ureter of each animal was blocked with a legating clip (He-
moclip Plus; Weck Closure Systems). The peritoneum was ﬂooded
with ADEPT (4% icodextrin solution) to prevent postsurgical adhe-
sions before closing. Themuscle wall was closed with single crossover
stitching using dissolvable stitches. After UUO, mice were provided
with buprenorphine (0.1 mg/kg) for 40 hours for analgesic purposes.
Figure 10. TG2 extracellular location depends on the HS chains of HSPGs. Kidney
cryosections were treated with 50 mU/ml protease-free heparitinase I (Hep-I) for 2
hours at 37°C. Extracellular TG2 was immunolabeled using mouse anti-TG2 IA12
antibody followed by goat anti-mouse DyLight 594. Images were obtained by con-
focal microscopy (A) and the level of extracellular TG2 was quantiﬁed by ImageJ in-
tensity analysis in four kidneys per treatment (B). Three ﬁelds are shown per treatment,
representative of control and AAN ﬁbrotic kidneys (A).
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Mice were allowed to recover and had free access to food and water.
Kidneys were harvested at days 7, 14, and 21 (Supplemental Table 1).
AAN was induced in 8-week-old male C57BL/6J and Sdc4-KO
mice by intraperitoneal injection of AAI (Sigma-Aldrich).52 Admin-
istration of AAI, 3 mg/kg, once every 3 days for 3 or 6 weeks, as
described in Supplemental Table 2, established progressive ﬁbro-
sis.32,50 Control animals received intraperitoneal injection of vehicle
control DMSO (Sigma-Aldrich). Mice were maintained at 20°C and
45% humidity on a 12-hour light/dark cycle and allowed free access
to standard rodent chow and water.
All procedures were carried out under license according to
regulations laid down by Her Majesty’s Government, United King-
dom (Animals Scientiﬁc Procedures Act, 1986).
Kidney Function
Terminal blood samples were taken. Twenty-
four-hour urine samples were collected using
metabolic cages 24 hours before termination.
Serum and urine creatinine was measured as
previously described Q:4,32,50 with modiﬁcations
detailed in the Supplemental Methods.
Fibrosis Measurement
Kidney ﬁbrosis was assessed on kidney sections
stained with MTas previously described Q:5.32,50 To
assess the scarring index in the UUO study, 10
images per kidney were acquired at 3200 mag-
niﬁcation. For the AAN model, the measure-
ment was performed using images acquired at
3100 magniﬁcation along the whole cortical
area of each kidney.
Immunohistochemistry
Immunodetection of collagens was performed
on 4-mm parafﬁn sections. After antigen re-
trieval and blocking, sections were incubated
with primary antibodies against collagen I (rab-
bit anticollagen I; Abcam; 1:250) collagen III
(goat anticollagen III; Southern Biotech; 1:10)
or collagen IV (rabbit antihuman collagen IV;
MP Biomedicals; 1:35). AlexaFluor 568 (UUO
model) or AlexaFluor 488 (AAN model) sec-
ondary antibodies (Invitrogen; 1:200) were
used for the immunoﬂuorescent staining, and
coverslips were mounted with 49,6-diamidino Q:6-
2-phenylindole (DAPI)-containing Vectashield
(Vectorlab). Ten nonoverlapping images of the
cortical regions were acquired at 3200 magni-
ﬁcation and analyzed using multiphase image
analysis with correction to DAPI staining.
Immunodetection of extracellular TG2 was
performed on 14-mm-thick cryostat sections, as
previously described by Johnson et al. in 1999
and 20031,12 and reported in the Supplemental
Methods.We usedmousemonoclonal anti-TG2 (clone ID10; Abcam;
1:100) followed by goat anti-mouse AlexaFluor 568 (Invitrogen;
1:200), or mouse anti-TG2monoclonal IA12 (University of Shefﬁeld;
1:100), followed by goat anti-mouse IgG DyLight 594 (Abcam;
1:200). Coverslips were mounted with DAPI-containing Vectashield.
For TG2 quantiﬁcation, ten3200 pictures of the cortical region were
acquired for each kidney and analyzed as described above.
TG2 and Sdc4 double staining was performed using rabbit
polyclonal anti- Sdc4 (Zymed; 1:50) and mouse anti-TG2 IgG
monoclonal IA12 (University of Shefﬁeld, United Kingdom; 1:100)
followed by donkey anti-rabbit IgG AlexaFluor 488 (Invitrogen;
1:200) and goat anti-mouse IgGDyLight 594 (Abcam; 1:200). HS and
TG2 dual staining was performed using mouse IgM anti-HS antibody
(Amsbio, 1:50) and rabbit polyclonal anti-TG2 (Abcam, 1:50)
followed by goat anti-mouse IgM FITC (Sigma-Aldrich; 1:100) and
Figure 11. Sdc4-KO lowers TGF-b1 in the AAN model of CKD. Active TGF-b (A), total
TGF-b (B), and percentage of activated TGF-b (C) were evaluated in WT and Sdc4-KO
kidneys using the mink lung TGF-b bioassay, as described in the Concise Methods.38
Total TGF-b was converted to a biologically active form for analysis by acid activation.
The percentage of activation was calculated by expressing the level of active TGF-b as
a percentage of total TGF-b. (D) Recombinant TGF-b standard curve. Values are the
mean of four kidneys6SEM, each assessed in triplicate. RLU, relative light unit.
*P,0.05 compared with the control or compared with Sdc4 KO AANQ:12 .
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donkey anti-rabbit IgG AlexaFluor 568 (Invitrogen; 1:200) in Tris-
buffered saline with Tween-20 containing 1% vol/vol serum (donkey
and goat). The dual staining protocol is described in the Supplemental
Methods. Images were captured using a Leica
SP5 confocal microscope scanning system cou-
pled to a340 and363 oil immersion objective-
inverted microscope. Successive serial optical
sections (0.5–1 mm) were recorded over a range
of specimen planes (3–7 mm). Colocalization
was estimated as described in Supplemental
Methods.
Enzymatic Pretreatment
Proteinase-free heparitinase I (EC 4.2.2.8)
(Sigma-Aldrich) was used to digest the side
chains of HSPG. Enzymatic pretreatments of
cryosections were performedwith heparitinase I
(0.05 U/ml) dissolved according to the manu-
facturer’s instructions and incubated for 2 hours
at 37°C.53 TG2 was detected by immunoﬂuores-
cence as described earlier. Extracellular TG2 was
quantiﬁed using the WCIF ImageJ integrated
density tool, which is a measure of pixel inten-
sity. All images were processed for background
noise subtraction before analysis for intensity.
Four kidneys were analyzed per treatment (ap-
proximately three sections per kidney; four to
seven nonoverlapping images per section).
Detection of TG In Situ Activity
In situ activity was detected as previously de-
scribed by Huang and colleagues26 Q:7–28 using 0.1
mMTexas red cadaverine instead of biotinylated
cadaverine.
TGF-b1 Activity
Active and total TGF-b1 were determined using
the MLEC luciferase TGF-b quantitative bioas-
say as previously described Q:8.38 Details are pro-
vided in the Supplemental Methods.
Statistical Analyses
Data are shown as mean6SEM. Data analyses
were performed using two-way ANOVA fol-
lowed by a Bonferroni post hoc test or a t test.
A probability of 95% (P,0.05) was taken as
indicating a statistically signiﬁcant result.
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